DDMAC Letter Cites Pfizer Geodon Ad For Implying Superiority To Haloperidol
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA also points to the journal ad’s lack of discussion of specific warnings for metabolic side effects and movement disorders.
You may also be interested in...
Antipsychotic Not Certain Savior For Forest
Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.
Antipsychotic Not Certain Savior For Forest
Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.
Novartis Exelon Promotion Cited By FDA For Unsubstantiated Superiority Claims To Aricept
Professional file card for the Alzheimer's medication is misleading because it is based on an inadequate study, FDA warning letter says.